Eckert & Ziegler

The stock of Eckert und Ziegler has moved up from its yearly low but remains in a medium- to long-term downtrend. Analysts at NuWays expect an acceleration of earnings growth ahead of the Q3 results on November 12, driven by higher profitability in the Isotope Products division as well as rising sales of lutetium‑177 and licence income. Technically, the stock must overcome short-term hurdles around €13, just under €14 and the 200-day line at roughly €14.40; on the downside it needs to hold €12.50/€12.60, otherwise a retest of the yearly low at €12 looms. » Mais em finanzen.net

Eckert & Ziegler has signed an agreement with Dutch provider TerThera for the supply of the radionuclide terbium-161 for radioligand therapies. Terbium-161 is to be added to Eckert & Ziegler’s portfolio in Brazil to shorten the supply chain and improve regional access to theranostic solutions. The news helped the stock move off its year low, but a sustainable bottoming has not yet been achieved. » Mais em finanzen.net

Eckert und Ziegler has once again confirmed its targets for 2026: revenue around €320 million and adjusted EBIT of about €80 million. Investors are responding cautiously, the stock is generally moving downward and the chart technicals signal further pressure. Adjusted for currency effects and the licensing business, reported revenue and earnings show growth, but real growth is significantly more moderate. » Mais em finanzen.net